Quantum-Si Incorporated - QSI STOCK NEWS

Quantum-Si (Nasdaq: QSI) has announced a strategic partnership with IDEX Health & Science for the development and manufacturing of the optics module for their Proteus™ proteomics platform. IDEX Health & Science, a global leader in life science optics, fluidics, and microfluidics, will leverage their expertise through their Melles Griot and Semrock product lines to support the design, development, and manufacturing of the Proteus optics module.

The partnership aims to utilize IDEX's experience in complex optical systems for life sciences instrumentation, with QSI targeting to bring the novel platform to market by the second half of 2026. The collaboration is expected to accelerate scientific advancements and mitigate risks associated with timelines and product launches, ultimately contributing to breakthroughs in drug discovery, diagnostics, and human health.

Quantum-Si (Nasdaq: QSI) announced its participation in the Festival of Genomics UK, scheduled for January 29-30, 2025, at ExCeL London. Dr. Richard Broadhead will present on Next-Generation Protein Sequencing™ and its impact on proteomics research, featuring the company's Platinum® Pro platform.

The presentation will showcase three key advancements:

• A new Protein Barcoding Kit for multiplexed peptide barcoding
• Library Prep Kit V2 for streamlined sample preparation
• Integrated software for unified data generation and analysis

The technology enables single-molecule protein sequencing with high precision in protein identification and proteoform characterization, particularly in distinguishing proteoforms from amino acid changes, alternative splicing, and post-translational modifications. This capability enhances the integration of proteomic data with genomic and transcriptomic research.

Quantum-Si (QSI) has announced the granting of 44,893 restricted stock units (RSUs) to new employees through its 2023 Inducement Equity Incentive Plan. The grants, approved by the Compensation Committee of QSI's Board of Directors, serve as inducement material for new hires in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will follow a vesting schedule where 25% will vest on March 20, 2026, with the remaining portion vesting in 12 equal quarterly installments thereafter. Vesting is contingent upon continued employment with the company. These equity awards are exclusively granted to individuals who were not previously QSI employees, as part of their employment compensation package.

Quantum-Si (Nasdaq: QSI) launches Platinum® Pro, a new benchtop sequencer aimed at revolutionizing protein analysis in proteomics research. The system is now available for ordering and features a comprehensive, integrated workflow designed to simplify complex protein sequencing.

Key innovations include an enlarged touchscreen with an elegant user interface, flexible data analysis options (local and cloud-based), and a Pro Mode for custom application development through a Technology Access Program. The product is intended to democratize access to proteomics, providing tools for diverse applications from proteoform analysis to protein barcoding.

CEO Jeff Hawkins emphasizes Platinum Pro's role in making proteomics more accessible, while Chief Commercial Officer Todd Bennett highlights a new partnership with Avantor, which will expand the product's availability in the U.S. and Canada. The system is expected to drive new opportunities for breakthrough discoveries and will begin shipping in the first quarter.

For more information or to place an order, visit Quantum-Si's website.

Quantum-Si (Nasdaq: QSI) has released a new preprint demonstrating the integration of their benchtop Platinum® instrument with protein barcoding technology. The study showcases a novel workflow that enhances multiplexed protein analysis with improved sensitivity and accessibility compared to traditional methods like mass spectrometry.

The research validated eight peptide barcodes designed for minimal detection bias and maximum sensitivity, featuring a streamlined workflow that reduces sample input requirements and hands-on time to under one hour. The system demonstrated a ten-fold dynamic range for detecting low-abundance proteins.

The combination of QSI's Platinum® Pro instrument with their protein Barcoding Kit offers advantages over DNA barcodes by providing direct quantitative readout of protein expression and localization. This advancement has potential applications in protein engineering, targeted drug delivery, and nucleic acid therapy development.

Quantum-Si (QSI) has announced a registered direct offering of 15,625,000 shares of common stock priced at $3.20 per share, aiming to raise approximately $50 million in gross proceeds. The offering is expected to close around January 6, 2025, subject to customary closing conditions.

The company plans to use the net proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent for this offering, which is being conducted under an effective shelf registration statement on Form S-3 that was declared effective by the SEC on August 22, 2023.

Quantum-Si (QSI) announced a new preprint demonstrating its proprietary bioinformatics tool ProteoVue, designed for detecting and quantifying Single Amino Acid Variants (SAAVs). The tool is part of the Platinum Analysis Software for the company's Platinum benchtop instrument. ProteoVue enables detection of protein variations, quantification of post-translational modifications, and characterization of proteins with unnatural amino acids.

The software leverages advanced signal processing, neural network-driven kinetic signature modeling, and clustering framework to provide insights into protein variants, including those undetectable by mass spectrometry. This development aligns with QSI's recent collaboration with NVIDIA to enhance sequencing performance through AI and follows the announcement of their next-generation platform, Proteus.

Quantum-Si (QSI) has announced that its Board's Compensation Committee has granted 46,666 restricted stock units (RSUs) to new employees under the company's 2023 Inducement Equity Incentive Plan. The RSUs were granted as an inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule includes 25% vesting on December 20, 2025, followed by the remaining amount vesting in 12 equal quarterly installments, contingent on continued employment.

Quantum-Si (Nasdaq: QSI) has announced a significant expansion of its international distribution network, now totaling 15 partners. The expansion covers multiple regions including Western and Eastern Europe, Asia, Middle East, Africa, South America, and the South Pacific. This strategic move, combined with the recently announced Avantor distribution agreement for North America, aims to accelerate the global adoption of their Platinum® product and drive revenue growth from 2025 onwards. The company is focusing on broadening access to research customers globally through these partnerships.